Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aspira Women's Health (AWH)
NASDAQ:AWH
Holding AWH?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.3Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: -53.66%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted growth in test volumes and significant achievements such as the New York State approval for OvaWatch and a major federal award for ENDOinform development. However, challenges such as severe weather impacting growth, increased expenses, and decreased cash reserves were noted. Despite these issues, the call emphasized strategic initiatives and improvements in margins, portraying a cautiously optimistic outlook.Company Guidance
During the third quarter of 2024, Aspira Women's Health Incorporated experienced a 4% growth in OvaSuite tests, delivering over 6,000 tests compared to approximately 5,783 in the same period in 2023. Despite severe weather, including Hurricane Helene, impacting key markets, the number of tests per sales representative rose by 21% over the first nine months of 2024 compared to 2023. The OvaSuite revenue increased by 2% to $2.3 million, with an average unit price of $376, slightly lower than the previous year's $383. Gross margins improved to 60%, and the company reported a reduction in cash used in operating activities by 12%, totaling $2.9 million for the quarter. Aspira also secured a $10 million federal award for the development of ENDOinform, enhancing its standing in the diagnostic market, while expanding its commercial reach, notably through a partnership with BioReference labs for OvaWatch distribution.Increase in OvaSuite Test Volume
Delivered over 6,000 OvaSuite tests in Q3 2024, a 4% increase compared to the same period in 2023.
New York State Approval for OvaWatch
Received approval from the New York State Department of Health for OvaWatch, opening access to one of the nation's largest healthcare markets.
ARPA-H $10 Million Award
Secured a $10 million federal award for the development of ENDOinform, an endometriosis detection blood test, including access to expert advisors.
Improved Gross Margin
Gross margins improved to 60% in Q3 2024 compared to 59% in Q3 2023.
Decrease in Cash Used in Operations
Cash used in operating activities decreased by 12% in Q3 2024 compared to Q3 2023.
---
AWH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AWH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $0.82 | $0.74 | -9.76% |
| Aug 12, 2024 | $1.13 | $1.09 | -3.54% |
| May 15, 2024 | $2.90 | $2.78 | -4.14% |
| Mar 28, 2024 | $3.43 | $3.10 | -9.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aspira Women's Health (AWH) report earnings?
Aspira Women's Health (AWH) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Aspira Women's Health (AWH) earnings time?
Aspira Women's Health (AWH) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AWH EPS forecast?
AWH EPS forecast for the fiscal quarter 2024 (Q4) is -0.22.
---